oncodaily

I grew up around a lot of physicians,” begins Adrian Gottschalk, President and CEO of Foghorn Therapeutics, a biotech company redefining how we understand and treat complex diseases by targeting the chromatin regulatory system. “My late father was a professor…

If you have ever stepped into a major oncology congress, you’ve likely felt his presence before you saw him. His voice, distinct and commanding, cuts through a room not with volume, but with purpose. His laugh, genuine and disarming, puts…